AAD 2022 – New Long-Term Bimekizumab Complete Skin Clearance Data in Moderate to Severe Plaque Psoriasis in Adults

Returning guest, Dr. Jeff Stark, Head of US Medical Immunology at UCB, discusses new long-term complete skin clearance data for bimekizumab in the treatment of moderate to severe plaque psoriasis in adults that was presented at the American Academy of Dermatology (AAD) Annual Meeting 2022. 

Jeffrey Stark, MD, is the Head of Medical Immunology at UCB and is board-certified in both rheumatology and internal medicine. After completing training at Vanderbilt University and Emory University, he spent several years in full-time rheumatology practice in both private and academic clinical settings. In subsequent industry medical affairs roles, Dr. Stark has focused on medical education, advocacy, data generation, and highlighting the unmet needs of patients with immunologic diseases. In addition to his role at UCB, Dr. Stark serves as a board member of the American College of Rheumatology (ACR) Research Foundation and is a member of the Medical Advisory Board of the Georgia Chapter of the Lupus Foundation. Dr. Stark is also a past President of the Georgia Society of Rheumatology.

Liked it? Take a second to support healthprofessionalradio on Patreon!

0 Comments

Leave a Reply

You must be logged in to post a comment.